TORONTO, Sept. 19, 2012 /PRNewswire/ -- There's no doubt as to the revolutionary nature of the Myoguide Needle EMG Guided Injection System. This breakthrough technology, developed by Canada's Intronix Technologies (http://www.intronixtech.com), is now giving practitioners a powerfully superior, much safer way to deliver targeted injections of Botox®, and other medication, for myofascial pain, spasticity, fibromyalgia and even cosmetics. Yet the benefits of the Myoguide System just keep growing, particularly considering a new partnership with Ambu (http://www.ambuusa.com), a leading, global supplier of medical devices.
Teaming up at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 59th annual meeting (http://www.aanem.org/Meeting.aspx), both Intronix Technologies and Ambu will showcase the Myoguide System, as well as the complementary products that facilitate Myoguide performance and maximize patient care. The event, taking place Oct. 3-6, 2012 at J. W. Marriott Grande Lakes in Orlando, Fla., will inform today's leading neurologists, physiatrists and clinicians about the new Intronix-Ambu partnership firsthand and how the products support one another so naturally.
"With Ambu on our team, Intronix can now provide clinician customers with Ambu's Neuroline hypodermic needle electrodes and surface electrode product lines," says Dr. Evan Friedman, president of Intronix Technologies. "At the AANEM event, attendees will discover that we're uniquely able to offer a complete clinical package for managing pain, movement disorders, spastic muscle management and cosmetic applications a convenient benefit for all. Ambu has a stellar reputation for manufacturing and distributing excellent medical devices, and we're proud to affiliate with such an industry leader. Ambu's solid distribution network will give Myoguide full exposure throughout the North American healthcare community."
Myoguide is also showcasing during the American Academy of Physical Medicine and Rehabilitation (AAPM&R)Annual Assembly, taking place Nov. 15-18, 2012 at Atlanta's Georgia World Congress Center, and at the International Neurotoxin Association (INA) "TOXINS 2012" conference, Dec. 5-8, 2012 at the Eden Roc Renaissance in Miami Beach, Fla.
Ambu (AMBU-B Copenhagen A/S) develops, produces and markets diagnostic and life-supporting devices for hospitals and rescue services. Its most notable products include artificial-respiration ventilation solutions and single-use electrodes for ECG tests and neurophysiological mappings. With corporate headquarters in Ballerup, Denmark and the United States headquarters in Glen Burnie, Md., Ambu employs approximately 1,700 people worldwide. For more information, visit www.ambuusa.com or contact Dan Toomey: email@example.com.
About Intronix Technologies Corporation
Located just outside Toronto, Ontario, Intronix Technologies Corp. designs and produces progressive electromyographic (EMG) systems for applications in the diagnosis and management of myofascial pain, spasticity, and fibromyalgia. Its innovations in injection guidance provide technology that drives clinical solutions to deliver confidence, improve workflow efficiency, and provide a better patient experience. Intronix Technologies is known for its exceptional equipment, plus its comprehensive customer-support programs that are developed to maximize the lifecycle value of equipment through responsive service maintenance and significant software support.
Dr. Evan Friedman
President, Intronix Technologies Corp.
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.
SOURCE Intronix Technologies Corporation